Mayne Pharma Group Limited
MAYNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -8.5% | 6.3% | 6.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 59.7% | 61.4% | 56.4% | 39.5% |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | 9% | 11.5% | 11.7% | -58.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -35% | -12% | -51.7% | -37.5% |
| EPS Diluted | -0.89 | -0.25 | -1.24 | -0.87 |
| % Growth | -256% | 79.8% | -42.5% | – |
| Operating Cash Flow | $0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | $0 | -$0 |